Jorge Santiago-Ortiz, Ph.D.

Dr. Santiago-Ortiz obtained his PhD in Chemical & Biomolecular Engineering from University of California, Berkeley with a minor in Cell Biology. During his career, Dr. Santiago-Ortiz has held multiple industry experiences over a span of 8+ years including directed evolution of adeno-associated virus (AAV) capsid proteins, engineering of structural and enzymatic proteins of HIV1-based Lentiviral vectors, library cloning, delivery of CRISPR-Cas9 transposon-based mutagenesis, randomized codon insertional mutagenesis, and design & cloning of vectors.

Choosing a CDMO: Top 10 Intangibles Biotech Firms Should Consider

October 22, 2020 Jorge Santiago-Ortiz, Ph.D. Biopharma

If your start-up company has developed a biological product and is planning to file an investigational new drug (IND) application with the FDA or register the product with another federal agency, and you don’t have …